NCT02693197View on ClinicalTrials.gov

PK Study of T-817 in Subjects With Hepatic Impairment

PHASE1CompletedINTERVENTIONAL

Enrollment

36

Participants

Timeline

Start Date

February 29, 2016

Primary Completion Date

August 31, 2016

Study Completion Date

August 31, 2016

Conditions

HealthyHepatic Impairment

Interventions

DRUG

T-817MA

A single oral dose of 448 mg

Trial Locations (2)

Unknown

University of Miami, Miami

Orlando Clinical Research Center, Orlando

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Celerion

INDUSTRY

lead

FUJIFILM Toyama Chemical Co., Ltd.

INDUSTRY